The study results indicate that TLE-CHM is not a cost-effective first-line treatment for HER2-negative advanced G/GEJ adenocarcinoma compared to chemotherapy alone, from the perspective of the Chinese healthcare system. The gene discussed is CHM; the disease is gastroesophageal junction adenocarcinoma.